We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Watson Pharmaceuticals has announced positive top-line data from two Phase III studies of silodosin, the company's investigational drug being studied for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH).
Merck Serono announced positive results from a Phase III study of Phenoptin (sapropterin dihydrochloride), in combination with diet, in patients 4 to 12 years old.
Ipsen has submitted a new drug application (NDA) to the FDA for Somatuline Autogel (60, 90 and 120 mg) in the United States as 28-day sustained-release formulation to treat patients with acromegaly, a disorder caused by the over-production of growth hormone secondary to a benign tumor of the anterior pituitary gland.
Dendreon announced that the FDA has assigned priority review status to the company's biologics license application (BLA) for Provenge (sipuleucel-T), its investigational active cellular immunotherapy for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer.
Hana Biosciences announced that the FDA has granted orphan drug designation to its drug Marqibo (vincristine sulfate liposomes injection) for the treatment of adult patients with acute lymphoblastic leukemia (ALL).
RxBio has announced that its lead product, RX100, has been shown to protect against lethal, whole-body radiation when administered before, during or up to several hours after exposure.
Researchers at the Stanford University School of Medicine have used the drug Valcyte (valganciclovir) -- an antiviral often used in treating diseases caused by human herpes viruses -- to treat a small number of chronic fatigue syndrome (CFS) patients.
BioCryst Pharmaceuticals has initiated a pivotal trial of its lead oncology drug, Fodosine, in the treatment of patients with relapsed or refractory T-cell leukemia/lymphoma.
Merck Serono announced that patient enrollment has been completed in the CLARITY study, a Phase III pivotal clinical trial evaluating the efficacy and safety of Merck Serono's proprietary oral formulation of cladribine for the treatment of relapsing forms of multiple sclerosis (MS).